Drug Profile
Sacituzumab govitecan - Immunomedics
Alternative Names: GS-0132; hRS7-SN38 antibody drug conjugate; IMMU-132; IMMU0132; Isactuzumab govitecan; Sacituzumab govitecan-hziy; TRODELVY; Trodelvy; TROP-2-SN-38Latest Information Update: 24 Jan 2024
Price :
$50
*
At a glance
- Originator Gilead Sciences; IBC Pharmaceuticals; Immunomedics; UNICANCER
- Developer Clovis Oncology; Gilead Sciences; Immunomedics; M. D. Anderson Cancer Center; Merck Sharp & Dohme; Pfizer; UNICANCER; University of Wisconsin Comprehensive Cancer Center; Yale University
- Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Indolizines; Monoclonal antibodies; Pyrans; Quinolines
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Triple negative breast cancer; Urogenital cancer
- Registered HER2 negative breast cancer
- Phase III Non-small cell lung cancer; Solid tumours
- Phase II Bladder cancer; Cervical cancer; Endometrial cancer; Prostate cancer
- Phase I/II Cancer
- No development reported Glioblastoma
Most Recent Events
- 22 Jan 2024 Efficacy and adverse events data from phase III EVOKE-01 trial in Non-small cell lung cancer released by Gilead Sciences
- 05 Dec 2023 Efficacy and adverse events data from a phase II trial in Breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)
- 05 Dec 2023 Efficacy data from phase III ASCENT trial in Triple-negative-breast-cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)